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Different Fever Deﬁnitions and the Rate of Fever and Neutropenia Diagnosed in
Children With Cancer: A Retrospective Two-Center Cohort Study
Patrizia Binz,1 Nicole Bodmer, MD,2 Kurt Leibundgut, MD,1 Oliver Teuffel, MD, Msc,1 Felix K Niggli, MD,2 and
Roland A Ammann, MD1*
INTRODUCTION
Fever and neutropenia (FN), speciﬁcally fever in severe che-
motherapy-induced neutropenia, is the most frequent potentially
lethal complication of chemotherapy in pediatric and adult
patients with cancer [1]. The current management with emergency
hospitalization and empirical administration of intravenous broad-
spectrum antibiotics has decreased mortality to below 1% in
pediatric FN [2]. The two criteria deﬁning FN directly inﬂuence
whether the diagnosis of FN is made or not. These criteria thus
have important implications on individual patient management,
treatment-related mortality, and costs in pediatric oncology [3].
The ﬁrst criterion, severe neutropenia, is quite uniformly deﬁned
and applied in pediatric oncology practice, as an absolute neutro-
phil count 0.5 G/L or 1.0 G/L and expected to rapidly decline
[1]. The second criterion, however, the temperature limit deﬁning
fever, relevantly varies between different pediatric oncology cen-
ters, even within the same country [4]. The temperature limit
clinically applied varied from 37.5 to 39.08C in 21 centers in
the United Kingdom in 2005 [5], and from 38.0 to 39.08C in 9
centers in Switzerland in 2012 (unpublished data). The tempera-
ture limit reported in 24 recently reviewed [6] original research
articles on pediatric FN published in 2010 and 2011 varied as well
from 37.5 to 39.08C (Fig. 1). Current guidelines on the manage-
ment of pediatric FN, developed by an international panel of 21
experts, do not discuss a temperature limit deﬁning fever [7].
By deﬁnition, the application of higher temperature limits
deﬁning FN should decrease the rate of FN diagnosed, but might
increase the rate of FN with complicated bacterial infections
because of delayed diagnosis and start of empirical antimicrobial
therapy. We do not know of any published results of retrospective
or prospective studies on such associations.
This study aimed to explore if different temperature limits
deﬁning fever were associated with differences in the rate of
FN, and of FN with bacteremia, in pediatric patients with cancer.
METHODS
Study Design and Patients
This retrospective cohort study was conducted in two pediatric
oncology centers in Switzerland. All children and adolescents up
to 17 years diagnosed with a malignancy requiring chemotherapy
between January 1, 2004 and June 30, 2011 were eligible for this
study. Patients were identiﬁed through the centers’ patient lists
and the Swiss Childhood Cancer Registry. Information about
chemotherapy, FN episodes, and 12 clinical characteristics poten-
tially associated with FN (see Table I) [1,8] were extracted from
patient charts by the ﬁrst author (PB). This study was approved by
the institutional review board with waiver of informed consent.
Definitions
Severe neutropenia was always deﬁned as absolute neutrophil
count 0.5 G/L [1,2]. Different deﬁnitions for fever were used. In
center 1, fever was deﬁned throughout the entire study period as
an ear temperature 38.58C persisting for 2 hours, without limit
for a single temperature (low deﬁnition). In center 2, fever was
Background. The deﬁnition of fever, and thus fever and neutro-
penia (FN), varies between different pediatric oncology centers.
Higher temperature limit should reduce FN rates, but may increase
rates of FN with complications by delaying therapy. This study
determined if different fever deﬁnitions are associated with different
FN rates. Procedure. Two pediatric oncology centers had used three
fever deﬁnitions in 2004–2011: ear temperature 38.58C persisting
2 hours (low deﬁnition); axillary temperature 38.58C 2 hours
or 39.08C once (middle); and ear temperature 39.08C once
(high). Clinical information was retrospectively extracted from
charts. FN rates were compared using mixed Poisson regression.
Results. In 521 pediatric patients with cancer, 783 FN were
recorded during 6,009 months cumulative chemotherapy exposure
time (501 years; rate, 0.13/month [95% CI, 0.12–0.14]), 124 of
them with bacteremia (16%; 0.021/month [0.017–0.025]). In
univariate analysis, the high versus low fever deﬁnition was associ-
ated with a lower FN rate (0.10/month [0.08–0.11] vs. 0.15/month
[0.13–0.16]; rate ratio, 0.66 [0.45–0.97]; P ¼ 0.036), the middle
deﬁnition was intermediate (0.13/month [0.11–0.15]). This differ-
ence was not conﬁrmed in multivariate analysis (rate ratio, 0.94
[0.67–1.33]; P ¼ 0.74). The high versus low deﬁnition was not
associated with an increased rate of FN with bacteremia (multivari-
ate rate ratio, 1.39 [0.53–3.62]; P ¼ 0.50). Conclusion. A higher
fever deﬁnition was not associated with a lower FN rate, nor with
an increased rate of FN with bacteremia. These may be false nega-
tive ﬁndings due to methodological limitations. These questions,
with their potential impact on health-related quality of life, and
on costs, need to be assessed in prospective studies. Pediatr Blood
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deﬁned from January 1, 2004 to July 8, 2007 as an axillary
temperature 38.58C persisting for 2 hours, or a single axillary
temperature 398C (middle) [8], and from July 9, 2007 to the end
of the study period as a single ear temperature 398C (high). The
maximum temperature measured at home or in the emergency
department was used. If clinically indicated, the attending physi-
cians in both centers were free to diagnose FN and to treat
patients accordingly even if these temperature limits had not
been reached.
FN was differentiated into episodes with and without bacter-
emia as a clinically important and well-deﬁned complication.
Aerobic and anaerobic blood cultures were taken at presentation
with FN before starting antimicrobial therapy. Subsequent blood
cultures were taken if patients remained febrile, or when they
had shaking chills. Blood cultures were drawn from each lumen
of existing central venous catheter, where applicable, or from
peripheral venous lines. Peripheral and central cultures were not
performed in parallel. Bacteremia was deﬁned as at least one
positive blood culture, irrespective of the pathogen detected,
using a qualitative automated culture system (BacT/ALERT, bio-
Me´rieux, Geneva, Switzerland; or BACTEC, Becton Dickinson,
Basel, Switzerland) [2,9].
Chemotherapy was classiﬁed into four levels of myelosuppres-
sive intensity according to the expected duration of severe neu-
tropenia: level 1, no severe neutropenia expected; levels 2 versus
3, 10 versus >10 days severe neutropenia expected; and level 4,
myeloablative chemotherapy requiring autologous hematopoietic
stem cell rescue [10,11]. Myeloablative chemotherapy preceding
allogeneic bone marrow transplantation was excluded from anal-
ysis. Chemotherapy exposure time was deﬁned as the cumulative
duration of chemotherapy plus 3 weeks accounting for neutrope-
nia developing after cessation of chemotherapy [1,8]. Because
characteristics related to therapy and course of disease (e.g.,
chemotherapy intensity or relapse) could change over time, dif-
ferent observation periods per patient could be deﬁned. During
each observation period, all characteristics potentially associated
with FN had to remain constant [8].
Clinical Management of Fever in Neutropenia
During the entire study period, routine management for
patients with cancer presenting with FN was emergency hospital-
ization and empirical broad-spectrum intravenous antimicrobial
therapy. The ﬁrst-line therapy was meropenem monotherapy in
center 1, and a combination of ceftriaxone plus amikacin in
center 2 [8].
Measures to Increase Data Quality
Three measures were used in order to compensate for the
drawbacks of the retrospective study design. First, the centers’
patient lists were supplemented by information from the Swiss
Childhood Cancer Registry in order to maximize patient cover-
age. Second, information on FN episodes from the prospective
SPOG 2003 FN study [2,9], which had recruited patients from
2004 to 2007 in both centers, was used in order to maximize
coverage of FN episodes. This information was as well used to
calculate an improved estimate of the FN rate. Third, the senior
author (RAA) made a plausibility check of data on chemotherapy
intensity and duration.
Power Analysis
The second hypothesis, that is, that a higher fever deﬁnition
may be associated with a higher rate of FN with bacteremia, was
used for a one-sided power analysis on Poisson distributed data
[12]. In order to reach 80% power, with alpha set at 5%, to detect
a 50% increase of the FN rate with bacteremia (standardized
difference, 0.5), 125 FN episodes with bacteremia were needed.
Assuming a proportion of FN with bacteremia of 20% [1,2], this
corresponded to 625 FN episodes in total. With an estimated
cumulative annual incidence of 85 FN episodes in the two centers,
the study had to cover 7.5 years, that is, January 2004 to
June 2011. For FN the sample size of 625 FN episodes corre-
sponds to around 90% power to detect a 25% increase of the FN
rate (standardized difference, 0.25).
Statistical Analysis
Because of non-normally distributed data, medians, ranges,
and interquartile ranges (IQR) were calculated for continuously
measured variables. FN Poisson rates were calculated per month,
together with their unconditional exact 95% conﬁdence intervals
(CI).
Associations of characteristics potentially associated with FN,
and with FN with bacteremia, were assessed using univariate and
multivariate mixed Poisson regression, with chemotherapy expo-
sure time as rate multiplier, and with a random intercept per
patient [8,13]. For multivariate analysis, all characteristics statisti-
cally signiﬁcant in univariate analysis, plus fever deﬁnition as the
main variable of interest, were included into the model [12]. The
characteristics center and year of chemotherapy start were not
included in the multivariate model because of the important col-
linearity with fever deﬁnition.
P-values below 0.05 were considered signiﬁcant. All analyses
were performed using R 2.14.0 (R Foundation for Statistical
Computing, Vienna, Austria). Speciﬁcally, the glmmPQL proce-
dure was used for mixed Poisson regression [14].
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Fig. 1. Different fever deﬁnitions used clinically and in research on
FN. Temperature limits are indicated as temperature persisting for
1–4 hours/single temperature (NA, not applicable). The bars indicate
frequencies, differentiated into clinically used deﬁnitions in 21
pediatric oncology centers in the United Kingdom 2005 (black) [5]
and 9 centers in Switzerland 2012 (light gray), and deﬁnitions used in
24 research articles published in 2010 and 2011 from different
countries (dark gray) [6]. The arrows indicate the three temperature
limits studied here.
800 Binz et al.
Pediatr Blood Cancer DOI 10.1002/pbc
RESULTS
Patients
A total of 521 patients were studied here, 310 (60%) treated in
center 1, and 211 (40%) in center 2, and 217 (42%) were female.
The median age at diagnosis of malignancy was 5.9 years (range,
2 days to 16.8 years; IQR, 2.5–11.6 years). Diagnoses were acute
lymphoblastic leukemia (ALL) in 161 (31%) patients, acute mye-
loid leukemia (AML) in 36 (7%), Hodgkin lymphoma in 41 (8%),
Non-Hodgkin lymphoma in 33 (6%), solid tumors outside the
TABLE I. Characteristics Associated With FN, Univariate Analysis
Characteristics
Rate of FN episodes Univariate analysis
Episodes Timea Rate (95% CI) Rate ratio (95% CI) P-value
Patient- and center-related characteristics
Pediatric oncology center
Center 1 481 3,274 0.15 (0.13–0.16) 1.33 (0.98–1.81) 0.070
Center 2 302 2,734 0.11 (0.10–0.12) Reference —
Fever definition
Low (38.5/NA 8C, center 1) 481 3,274 0.15 (0.13–0.16) Reference —
Middle (38.5/39.08C, center 2) 141 1,080 0.13 (0.11–0.15) 0.89 (0.59–1.33) 0.57
High (NA/39.08C, center 2) 161 1,654 0.10 (0.08–0.11) 0.66 (0.45–0.97) 0.036
Sex
Male 413 3,591 0.12 (0.10–0.13) Reference —
Female 370 2,417 0.15 (0.14–0.17) 1.33 (0.99–1.79) 0.060
Age at diagnosis
<4 years 268 2,025 0.13 (0.12–0.15) Reference —
4.00–7.99 years 214 1,665 0.13 (0.11–0.15) 0.97 (0.66–1.42) 0.88
8.00–11.99 years 132 1,049 0.13 (0.11–0.15) 0.95 (0.61–1.48) 0.82
12 years 169 1,270 0.13 (0.11–0.15) 1.01 (0.67–1.52) 0.98
Disease-related characteristics
Diagnostic group
Acute lymphoblastic leukemia 314 3,021 0.10 (0.09–0.12) Reference —
Acute myeloid leukemia 110 406 0.27 (0.22–0.33) 2.61 (1.65–4.11) <0.001
Hodgkin lymphoma 10 193 0.05 (0.02–0.10) 0.50 (0.13–1.86) 0.30
Non-Hodgkin lymphoma 50 272 0.18 (0.14–0.24) 1.77 (0.95–3.31) 0.074
Solid tumor outside the CNS 226 1,358 0.17 (0.15–0.19) 1.60 (1.12–2.29) 0.010
Tumor of the CNS 73 759 0.10 (0.08–0.12) 0.93 (0.54–1.58) 0.78
Relapse/second malignancy
Unrelapsed first malignancy 692 5,512 0.13 (0.12–0.14) Reference —
Relapse or second malignancy 91 496 0.18 (0.15–0.23) 1.46 (0.91–2.33) 0.11
Characteristics of therapy and course
Myelosuppressive intensity of chemotherapyb
1: no severe neutropenia expected 104 2,226 0.05 (0.04–0.06) Reference —
2: severe neutropenia 10 days expected 519 3,296 0.16 (0.14–0.17) 3.37 (2.28–4.98) <0.001
3: severe neutropenia >10 days expected 140 441 0.32 (0.27–0.37) 6.79 (4.25–10.9) <0.001
4: myeloablative chemotherapy 20 46 0.44 (0.27–0.68) 9.37 (3.86–22.7) <0.001
Year of chemotherapy start
2004/2005 173 978 0.18 (0.15–0.21) 1.77 (1.10–2.85) 0.018
2006/2007 214 1,558 0.14 (0.12–0.16) 1.38 (0.88–2.16) 0.17
2008/2009 244 1,949 0.13 (0.11–0.14) 1.26 (0.81–1.95) 0.31
2010/2011 152 1,524 0.10 (0.08–0.12) Reference —
Central venous access device
None implanted 79 905 0.09 (0.07–0.11) Reference —
Central venous access device implanted 704 5,104 0.14 (0.13–0.15) 1.58 (0.96–2.61) 0.075
Bone marrow involvement
No 664 5,564 0.12 (0.11–0.13) Reference —
Yes (25% malignant cells) 119 444 0.27 (0.22–0.32) 2.24 (1.50–3.36) <0.001
Prior episodes of FN
No 319 2,679 0.12 (0.11–0.13) Reference —
Yes 464 3,329 0.14 (0.13–0.15) 1.17 (0.86–1.60) 0.32
Prior episodes of FN with bacteremia
No 658 4,948 0.13 (0.12–0.14) Reference —
Yes 125 1,060 0.12 (0.10–0.14) 0.89 (0.59–1.33) 0.56
FN, fever in severe chemotherapy-induced neutropenia; CNS, central nervous system; NA, not applicable. aCumulative time of chemotherapy
exposure in months; bSee Refs. 10,11.
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central nervous system (CNS) in 170 (33%), and CNS tumors in
80 (15%). 42 (8%) patients had a relapse or a second malignancy.
Chemotherapy
The cumulative chemotherapy exposure time in these 521
patients was 182,886 days (6,009 months, 501 years). The mye-
losuppressive intensity was 1 during 2,226 months, 2 during 3,296
months, 3 during 441 months, and 4 during 46 months. The entire
chemotherapy exposure time was recorded in 1,709 observation
periods (median per patient, 3; range, 1–12; IQR, 2–4) with a
median duration of 58 days (range, 1–731; IQR, 20–147).
Episodes of Fever in Neutropenia
During the cumulative chemotherapy exposure time of 6,009
months, 783 FN episodes were recorded (rate, 0.13 episodes per
month; 95% CI, 0.12–0.14). Bacteremia was detected in 124
(16%) of these 783 FN episodes (rate, 0.021 per month; 95%
CI, 0.017–0.025). Of the 521 patients, 302 (58%) had at least
one FN episode (median per patient, 1; IQR, 0–2; range, 0–11),
and 92 (18%) had at least one FN episode with bacteremia
(median per patient, 0; range, 0–4). Death was considered to be
caused by infection in ﬁve (0.6%) patients with FN episodes,
four of them with bacteremia, and one with rhinocerebral
mucormycosis [15].
An improved estimate of the FN rate was calculated based on
information from the second measure to increase data quality. In
the patients participating in the prospective SPOG 2003 FN study
between 2004 and 2007, 52 (21%) of the corresponding 247 FN
episodes had been reported only in SPOG 2003 FN, but were not
detected by retrospective chart review here. This proportion was
comparable between centers (18% vs. 25%). Extrapolating this
proportion to all patients in the entire time studied here led to an
increased estimate of 939 (plus 20%) instead of 783 FN episodes
in 6,009 months cumulative chemotherapy exposure time. This
corresponds to an increased rate estimate of 0.16 FN per month,
instead of 0.13.
Fever Definitions and the Risk to Develop FN
The rate of FN episodes per month was 0.15 (95% CI,
0.13–0.16) for the low fever deﬁnition. It was 0.13 (95% CI,
0.11–0.15) for the middle, and 0.10 (95% CI, 0.08–0.11) for the
high deﬁnition (Table I).
In univariate analysis, the high versus low fever deﬁnition was
associated with a signiﬁcantly lower FN rate (rate ratio, 0.66; 95%
CI, 0.45–0.97; P ¼ 0.036; Table I). Four of the remaining 11
characteristics, that is, diagnostic group (AML and solid tumor
outside the CNS, respectively, vs. ALL), chemotherapy intensity
(levels 2, 3, and 4 vs. level 1), bone marrow involvement, and the
time period of chemotherapy start (2004/05 vs. 2010/11) were all
signiﬁcantly associated with an increased FN rate. The other
seven characteristics, namely center, sex, age at diagnosis, relapse
status, central venous access device, prior episodes of FN, and
prior episodes of FN with bacteremia, were not signiﬁcantly
associated with the FN rate.
In multivariate analysis, when corrected for the three variables
diagnostic group, chemotherapy intensity, and bone marrow in-
volvement, fever deﬁnition was not signiﬁcantly associated any
more with the FN rate (high vs. low rate ratio, 0.94; 95% CI,
0.67–1.33; P ¼ 0.74; Table II). Diagnostic group (Hodgkin lym-
phoma and CNS tumor, respectively, vs. ALL), and chemotherapy
intensity (levels 2, 3, and 4 vs. level 1), were signiﬁcantly and
independently associated with the FN rate (Table II). Nearly the
entire variance was due to within-patient variance (t ¼ 0.000129,
s ¼ 1.85).
Fever Definitions and the Risk to Develop FN With
Bacteremia
The rate of FN episodes with bacteremia per month was 0.022
(95% CI, 0.017–0.028) for the low fever deﬁnition. It was 0.022
(95% CI, 0.014–0.033) for the middle, and 0.017 (95% CI,
0.011–0.024) for the high deﬁnition (Table III).
In univariate analysis, the high versus low fever deﬁnition was
not signiﬁcantly associated with the rate of FN with bacteremia
TABLE II. Characteristics Associated With FN, Multivariate Analysis
Characteristics Rate ratio (95% CI) P-value
Fever definition
Low (38.5/NA 8C, center 1) Reference —
Middle (38.5/39.08C, center 2) 1.05 (0.73–1.49) 0.80
High (NA/39.08C, center 2) 0.94 (0.67–1.33) 0.74
Diagnostic group
Acute lymphoblastic leukemia Reference —
Acute myeloid leukemia 0.53 (0.22–1.26) 0.16
Hodgkin lymphoma 0.26 (0.08–0.84) 0.025
Non-Hodgkin lymphoma 0.74 (0.38–1.43) 0.37
Solid tumor outside the CNS 0.79 (0.55–1.15) 0.22
Tumor of the CNS 0.50 (0.30–0.82) 0.007
Myelosuppressive intensity of chemotherapya
1: no severe neutropenia expected Reference —
2: severe neutropenia 10 days expected 4.14 (2.66–6.44) <0.001
3: severe neutropenia >10 days expected 10.2 (4.36–23.8) <0.001
4: myeloablative chemotherapy 13.6 (5.24–35.0) <0.001
Bone marrow involvement 1.26 (0.81–1.96) 0.30
FN, fever in severe chemotherapy-induced neutropenia; CNS, central nervous system; NA, not applicable. asee Refs. 10,11.
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(rate ratio, 0.77; 95% CI, 0.25–2.37; P ¼ 0.65; Table III). Three
of the remaining 11 characteristics, that is, diagnostic group
(AML vs. ALL), chemotherapy intensity (level 3 vs. level 1),
and bone marrow involvement were all signiﬁcantly associated
with an increased rate of FN with bacteremia, while the other
eight characteristics were not.
In multivariate analysis, when corrected for the three variables
diagnostic group, chemotherapy intensity, and bone marrow in-
volvement, fever deﬁnition was again not signiﬁcantly associated
with the rate of FN with bacteremia (high vs. low rate ratio, 1.39;
95% CI, 0.53–3.62; P ¼ 0.50; Table IV). Neither diagnostic
group nor bone marrow involvement was associated with the
TABLE III. Characteristics Associated With FN With Bacteremia, Univariate Analysis
Characteristics
Rate of FN episodes Univariate analysis
Episodes Timea Rate (95% CI) Rate ratio (95% CI) P-value
Patient- and center-related characteristics
Pediatric oncology center
Center 1 72 3,274 0.022 (0.017–0.028) 1.16 (0.46–2.88) 0.76
Center 2 52 2,734 0.019 (0.014–0.025) Reference —
Fever definition
Low (38.5/NA 8C, center 1) 72 3,274 0.022 (0.017–0.028) Reference —
Middle (38.5/39.08C, center 2) 24 1,080 0.022 (0.014–0.033) 1.01 (0.31–3.32) 0.99
High (NA/39.08C, center 2) 28 1,654 0.017 (0.011–0.024) 0.77 (0.25–2.37) 0.65
Sex
Male 64 3,591 0.018 (0.014–0.023) Reference —
Female 60 2,417 0.025 (0.019–0.032) 1.39 (0.58–3.36) 0.46
Age at diagnosis
< 4 years 50 2,025 0.025 (0.018–0.033) Reference —
4.00–7.99 years 25 1,665 0.015 (0.010–0.022) 0.61 (0.18–2.06) 0.42
8.00–11.99 years 13 1,049 0.012 (0.007–0.021) 0.50 (0.11–2.36) 0.38
 12 years 36 1,270 0.028 (0.020–0.039) 1.15 (0.39–3.41) 0.80
Disease-related characteristics
Diagnostic group
Acute lymphoblastic leukemia 55 3,021 0.018 (0.014–0.024) Reference —
Acute myeloid leukemia 35 406 0.086 (0.060–0.120) 5.04 (1.86–13.6) 0.001
Hodgkin lymphoma 0 193 0.000 (0.000–0.019) — —
Non-Hodgkin lymphoma 6 272 0.022 (0.008–0.048) 1.29 (0.18–9.33) 0.80
Solid tumor outside the CNS 22 1,358 0.016 (0.010–0.025) 0.95 (0.30–3.02) 0.93
Tumor of the CNS 6 759 0.008 (0.003–0.017) 0.46 (0.06–3.34) 0.44
Relapse/second malignancy
Unrelapsed first malignancy 110 5,512 0.020 (0.016–0.024) Reference —
Relapse or second malignancy 14 496 0.028 (0.015–0.047) 1.41 (0.35–5.78) 0.63
Characteristics of therapy and course
Myelosuppressive intensity of chemotherapyb
1: no severe neutropenia expected 14 2,226 0.006 (0.003–0.011) Reference —
2: severe neutropenia 10 days expected 68 3,296 0.021 (0.016–0.026) 3.28 (0.96–11.1) 0.057
3: severe neutropenia >10 days expected 39 441 0.088 (0.063–0.121) 14.1 (3.83–51.5) <0.001
4: myeloablative chemotherapy 3 46 0.066 (0.014–0.192) 10.4 (0.74–148) 0.083
Year of chemotherapy start
2004/2005 33 978 0.034 (0.023–0.047) 2.06 (0.53–7.94) 0.29
2006/2007 29 1,558 0.019 (0.012–0.027) 1.13 (0.28–4.55) 0.37
2008/2009 37 1,949 0.019 (0.013–0.026) 1.16 (0.31–4.33) 0.36
2010/2011 25 1,524 0.016 (0.011–0.024) Reference —
Central venous access device
None implanted 17 905 0.019 (0.011–0.030) Reference —
Central venous access device implanted 107 5,104 0.021 (0.017–0.025) 1.12 (0.31–4.08) 0.87
Bone marrow involvement
No 86 5,564 0.015 (0.012–0.019) Reference —
Yes (25% malignant cells) 38 444 0.086 (0.061–0.117) 5.53 (2.12–14.4) <0.001
Prior episodes of FN
No 51 2,679 0.019 (0.014–0.025) Reference —
Yes 73 3,329 0.022 (0.017–0.028) 1.15 (0.46–2.90) 0.76
Prior episodes of FN with bacteremia
No 93 4,948 0.019 (0.015–0.023) Reference —
Yes 31 1,060 0.029 (0.020–0.042) 1.56 (0.54–4.50) 0.41
FN, fever in severe chemotherapy-induced neutropenia; CNS, central nervous system; NA, not applicable. aCumulative time of chemotherapy
exposure in months; bSee Refs. 10,11.
Different Fever Definitions and the FN Rate 803
Pediatr Blood Cancer DOI 10.1002/pbc
rate of FN with bacteremia independently from chemotherapy
intensity (Table IV). Nearly the entire variance was due to
within-patient variance (t ¼ 0.000307, s ¼ 2.03).
DISCUSSION
There is no consensus on how to deﬁne fever, and thus FN, in
pediatric oncology. This is the ﬁrst study to assess the association
between different fever deﬁnitions and the rate of diagnosis of
FN. In this retrospective two-center study in pediatric patients
with cancer, a higher temperature limit deﬁning fever was not
associated with a reduced rate of FN diagnosed during chemo-
therapy. A signiﬁcant reduction of about one-third of the FN rate
was associated with the high versus low deﬁnition of fever, that is,
a single temperature of 39.08C versus a temperature 38.58C
persisting for 2 hours, only in univariate analysis (Table I).
When corrected for other FN risk factors in multivariate analysis,
this reduction was not conﬁrmed, and the FN rates in the three
fever deﬁnitions studied were nearly equal, with quite narrow
95% CI (Table II).
This ﬁnding would implicate that all children with a tempera-
ture 38.58C will reach as well a temperature 39.08C, which
contradicts clinical experience. We do think, however, that this
negative and counterintuitive result is due to three methodological
limitations of this study: First, the three temperature limits deﬁn-
ing fever studied here were all in a narrow range at the uppermost
border of the spectrum of temperatures reported (Fig. 1). This
may lead to false negative results. Comparing temperature limits
from opposite ends of the spectrum might increase the power to
detect existing differences. Second, the different fever deﬁnitions
were not independent from the centers: The low deﬁnition was
only implemented in center 1, while the middle and the high
deﬁnition were only implemented in center 2. Differences in the
distribution of cancer diagnoses, in the proportion of FN diagnoses
made clinically when the temperature limit deﬁning fever was not
reached, in chemotherapy, or in supportive therapy might system-
atically inﬂuence FN rates between centers besides fever deﬁni-
tions, allowing for important interaction effects. The temperature
limits used clinically could not be reliably assessed in this retro-
spective study. It was not possible to directly estimate these inter-
action effects, but at least center itself was not associated with
the FN rates. Third, the middle fever deﬁnition relied on axillary
temperature measurements, while ear temperature measurements
were used for the low and the high deﬁnitions. Compared to ear
temperature, measured by infrared tympanic thermometry, axillary
measurements are known to less reliably reﬂect core temperature,
and to systematically result in lower ﬁndings by around 0.68C [16].
This may have reduced the differences in core temperature between
different deﬁnitions. Speciﬁcally, this may have impaired those
comparisons which included the middle deﬁnition, but not compar-
isons between the high and the low deﬁnitions.
Furthermore, the rates of FN with bacteremia were not signiﬁ-
cantly different in the three fever deﬁnitions studied in univariate
or multivariate analysis (Tables III and IV). Though the corre-
sponding 95% CI were quite wide, a clinically relevant increase of
50% of the FN rate with bacteremia would have been detected
with 80% power according to the results of the power analysis.
Wide and clinically relevant variations in fever deﬁnitions are
known in pediatric oncology [5], and these variations have a
potentially large impact on individual patient management,
mortality associated with FN, and costs [3]. Despite this, we do
not know of any published results of research on the topic of this
study. A comparison of its main results with those of other
research groups is thus not possible.
Regarding secondary results, the FN rate of 0.13 per month of
chemotherapy found here was comparable to the rate of 0.12 per
month (1.48 per year) reported for the period from 1993 to 2004
in center 2 [8]. The proportion of FN episodes with bacteremia
was 16% and thus within the range of 10–24% reported earlier
[8,9,17–19]. The characteristics associated with FN with or
without bacteremia found here, that is, AML diagnosis, higher
intensity of chemotherapy, and bone marrow involvement, are all
well-known risk factors for FN [1]. Interestingly, the ﬁnding of
prior episodes of FN as an independent risk factor for FN and FN
with bacteremia, reported from center 2 before [8], could not be
replicated here.
TABLE IV. Characteristics Associated With FN With Bacteremia, Multivariate Analysis
Characteristics Rate ratio (95% CI) P-value
Fever definition
Low (38.5/NA 8C, center 1) Reference —
Middle (38.5/39.08C, center 2) 1.42 (0.54–3.76) 0.48
High (NA/39.08C, center 2) 1.39 (0.53–3.62) 0.50
Diagnostic group
Acute lymphoblastic leukemia Reference —
Acute myeloid leukemia 0.82 (0.08–8.39) 0.87
Hodgkin lymphoma —a —a
Non-Hodgkin lymphoma 0.65 (0.09–4.69) 0.67
Solid tumor outside the CNS 0.56 (0.18–1.73) 0.32
Tumor of the CNS 0.29 (0.05–1.72) 0.17
Myelosuppressive intensity of chemotherapyb
1: no severe neutropenia expected Reference —
2: severe neutropenia 10 days expected 4.58 (1.29–16.3) 0.019
3: severe neutropenia >10 days expected 12.2 (1.10–135) 0.042
4: myeloablative chemotherapy 24.9 (1.63–382) 0.021
Bone marrow involvement 2.45 (0.91–6.63) 0.077
FN, fever in severe chemotherapy-induced neutropenia; NA, not applicable. aNo FN with bacteremia in patients with Hodgkin lymphoma;
bSee Refs. 10,11.
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Strengths of this study include its two-center design; its large
size, with 521 patients representing the entire spectrum of pediat-
ric malignancies, with a cumulative chemotherapy exposure time
of 501 years, and with 783 FN, 124 of them FN with bacteremia;
and the use of mixed Poisson regression as a powerful tool to
analyze the speciﬁc kind of data studied. In addition to the three
methodological limitations discussed above, the retrospective de-
sign of this study entails the risk of missing patients, plus missing
and incorrect data. Three measures to increase data quality were
used to minimize these problems.
In conclusion, a higher temperature limit deﬁning fever was
not associated with a reduced rate of FN diagnosed during che-
motherapy in this study. Furthermore, a higher temperature limit
was not associated with an increased rate of FN with bacteremia.
The counterintuitive negative ﬁnding regarding the FN rate may
well be a false negative ﬁnding due to methodological limitations.
These might be overcome in adequately designed prospective
studies on higher versus lower temperature limits deﬁning fever
and thus FN. If future research could show that a higher tempera-
ture limit is both efﬁcacious, by reducing the rate of FN diagnosis,
and safe, by not relevantly increasing the rate of FN with com-
plications such as bacteremia, this would have an important im-
pact on health-related quality of life in pediatric patients with
cancer, and on costs.
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